
395 – Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer’s disease, & more
In this episode of The Drive podcast, Dr. Peter Attia and lipid expert Dr. Tom Dayspring delve into brain cholesterol metabolism. They first review peripheral lipidology: how cells synthesize cholesterol, the roles of HDL and LDL, the two families of apolipoproteins (ApoA and ApoB), and the concept of reverse cholesterol transport. A key point is that the brain operates independently—it cannot use circulating cholesterol. Instead, brain cells (especially astrocytes and oligodendrocytes) synthesize all cholesterol in situ. APOE is the main apolipoprotein in the brain, forming HDL-like particles to shuttle cholesterol to neurons. The APOE genotype (ε2, ε3, ε4) dramatically affects Alzheimer's risk: ε4 carriers have impaired cholesterol delivery, leading to neuronal membrane dysfunction, increased amyloid-beta 42 production, and tau pathology. Biomarkers like desmosterol (reflecting brain synthesis) and 24S-hydroxycholesterol (a neuron-derived metabolite) can be measured in plasma. Statins enter the brain and reduce cholesterol synthesis; while some patients report cognitive side effects, most meta-analyses show neutral or beneficial effects on dementia risk. Omega-3 fatty acids (EPA/DHA) are crucial for membrane fluidity and may support brain health, though randomized trial evidence is limited. Finally, CETP inhibitors like obicetrapib show promise by raising functional HDL particles that could cross the blood-brain barrier and rescue dysfunctional APOE4 particles. The discussion bridges lipidology, pharmacology, and Alzheimer's prevention, offering actionable insights for clinicians.






